Dimensional Fund Advisors LP Has $702.75 Million Stake in Medtronic PLC $MDT

Dimensional Fund Advisors LP lifted its holdings in Medtronic PLC (NYSE:MDT) by 2.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,379,881 shares of the medical technology company’s stock after buying an additional 154,209 shares during the period. Dimensional Fund Advisors LP owned about 0.58% of Medtronic worth $702,748,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Delos Wealth Advisors LLC acquired a new position in shares of Medtronic in the 2nd quarter valued at about $27,000. Corundum Trust Company INC acquired a new position in Medtronic in the 3rd quarter valued at approximately $27,000. Valley Wealth Managers Inc. purchased a new stake in Medtronic in the 3rd quarter worth approximately $29,000. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medtronic during the 3rd quarter valued at $33,000. Finally, Tripletail Wealth Management LLC purchased a new position in shares of Medtronic during the 3rd quarter valued at $34,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Trading Down 1.4%

NYSE:MDT opened at $96.71 on Wednesday. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The firm has a market cap of $124.16 billion, a price-to-earnings ratio of 26.94, a P/E/G ratio of 2.46 and a beta of 0.71. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The company’s 50 day moving average is $98.92 and its 200-day moving average is $96.99.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Insider Buying and Selling

In other news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Daiwa Securities Group cut their price objective on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, February 27th. Citigroup started coverage on Medtronic in a research note on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target for the company. JPMorgan Chase & Co. reduced their price target on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Sanford C. Bernstein increased their price objective on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Finally, Mizuho upgraded shares of Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.74.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).